Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial
2013
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
13
Citations
NaN
KQI